Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Extended Half-Life (EHL) Recombinant Factor IX
Treatment for Hemophilia
Typical Dosage: Prophylaxis: 50-100 IU/kg once weekly or every 10-14 days; On-demand: 10-60 IU/kg
Effectiveness
90%
Safety Score
68%
Clinical Trials
40
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Prophylaxis: 50-100 IU/kg once weekly or every 10-14 days; On-demand: 10-60 IU/kg
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
70(Treat 70 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$380,000
Monitoring:$5,000
Side Effect Mgmt:$5,000
Total Annual:$390,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$100,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$410,526.32
Comparison vs Standard Half-Life Recombinant Factor IX
Cost Difference
+$80,000/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Extended Half-Life (EHL) Recombinant Factor IX Outcomes
for Hemophilia
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Inhibitor development
+2%
Allergic reactions
+0.5%
Injection site reactions
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov